AstraZeneca beats Q2 profit estimates with $2.63 core EPS, keeps 2026 outlook
AI Market Summary
AstraZeneca reported Q2 results ahead of expectations, with core EPS up 18% to 2.63 and revenue up 5% to 15.38B at constant currency, while reaffirming 2026 guidance for low double-digit EPS growth and mid-to-high single-digit revenue growth. The beat and unchanged outlook help offset near-term pipeline concerns after a recent trial failure, supporting pharma-sector risk appetite in the short term.
Impact level
● Medium
Affected assets
NCSKASX2USD/USDT+2.47%
AI Insight · NCSKASX2USD/USDTAI Insight
▲ Bullish
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
AstraZeneca reported 2026 second-quarter core earnings per share of $2.63, up 18% year-on-year and above the market expectation of $2.48, while revenue rose 5% to $15.38 billion. The company maintained its full-year guidance for 2026, forecasting low double-digit growth in core EPS and mid-to-high single-digit revenue growth. A recent clinical trial failure has raised questions about the long-term outlook for its pipeline, but the quarter’s performance supported confidence in its current growth trajectory.
